摩罗丹治疗慢性萎缩性胃炎疗效的Meta分析

A Meta-analysis of therapeutic effect of Morodan on chronic atrophic gastritis

目的评价摩罗丹治疗慢性萎缩性胃炎(CAG)的临床效果。方法计算机检索万方、维普、CNKI、Pubmed数据库至2018年8月,纳入有关摩罗丹治疗CAG的临床随机对照试验,按照修改后的Jadad质量评价标准对纳入文献进行评价,使用Revman 5.3软件计算比值比(OR)及95%可信区间(95%CI),检验研究异质性及发表偏倚,对不能合并分析的研究进行描述性分析。结果共纳入12项研究,包括1678例患者。Meta分析结果显示:摩罗丹组与对照组相比,临床综合疗效、胃镜检查改善、胃黏膜组织病理总体改善、异型增生改善、症状改善方面显示出较好的疗效,但Hp转阴率两组之间差异无统计学意义。结论研究表明,摩罗丹治疗CAG效果良好,但仍需高质量的随机对照研究进一步的验证支持。

Objective To evaluate the clinical therapeutic effect on chronic atrophic gastritis(CAG) treated by Moluodan. Methods The database of Wanfang,Weipu,CNKI and PubMed was searched by computer until August 2018,and included in the clinical randomized controlled trials on the treatment of CAG by Morodan.According to the revised Jadad quality evaluation criteria,the included literature was evaluated.The ratio(OR) and 95% confidence interval(95%CI) were calculated by Revman 5.3 software to test the heterogeneity and publication bias.Descriptive analysis is done for research that could not be combined. Results A total of 12 studies were included,including 1678 patients.Meta analysis results showed that:Compared with the control group,the Morodan group showed better clinical efficacy,improved gastroscopy,overall improvement of gastric mucosal pathology,dysplasia and symptoms,but there was no statistical difference in the negative rate of Hp between the two groups. Conclusion Studies have shown that Morodan is effective in the treatment of CAG,but further validation support from high-quality randomized controlled trials is needed.